HER2-positive metastatic breast cancer treatment granted Priority Review
Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of HER2-positive metastatic breast cancer.
List view / Grid view
News
Sanofi announces voluntary recall of Zantac products
The pharmaceutical company Sanofi is voluntarily recalling its OTC Zantac products in the US and Canada due possible contamination with NDMA.
Concept discovered for fabricating nanomeshes as drug delivery system
The fight against antibiotic resistance could be improved with the discovery of a concept for fabricating nanomeshes as a drug delivery system.
Seven medicines recommended for approval by EMA
The EMA CHMP has given a positive opinion for marketing authorisation approval to seven medicines following its October meeting.
First non-injectable treatment for severe hypoglycaemia recommended
Marketing authorisation in the EU for Baqsimi, the first non-injectable treatment for very low levels of blood sugar, has been recommended by an EMA committee.
First patient enrolled on Phase II trial for cystic fibrosis treatment
A Phase II trial for an inhaled cystic fibrosis drug, intended for adults and adolescents, has enrolled its first patient.
Osteoarthritis therapeutics market to be worth $10.1bn by 2024, says report
A new report has said the osteoarthritis therapeutics market is estimated to grow due to rapid increase in the geriatric and obese population.
New report shows that clinical research improves health of UK economy
A new report has shown that from 2016/17 to 2018/19 clinical research has generated an estimated £8 billion of GVA for the UK.
Contracts signed to deliver urgent medicines into UK after Brexit
The DHSC and three companies have signed contracts worth £25 million to ensure that essential medicines can be supplied to the UK in 24 to 48 hours.
FDA issues warning letter to Torrent Pharmaceuticals
Torrent Pharmaceuticals has received a warning letter from the FDA for violating cGMP regulations at its manufacturing facility in India.
New breakthrough can effectively deliver medications into the brain
Scientists have found a way to effectively transport medication into the brain which could lead to improved treatments for neurological and neurodegenerative diseases.
First-in-class migraine treatment approved by FDA
Reyvow (lasmiditan), for the treatment of acute migraine, has received approval from the FDA following success in clinical trials.
XARELTO® approved to help prevent blood clots
The FDA has approved XARELTO® (rivaroxaban) to help prevent blood clots in acutely ill medical patients.
Clinical trial to investigate the use of CBD for Parkinson’s-related psychosis
A pioneering clinical study will assess the safety, tolerability and effectiveness of CBD in people with Parkinson's-related psychosis.
Female infertility drug market to exhibit CAGR of 3.4 percent
Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
